Neurotech International

We’ve wrapped up our time at the Ignite Investment Summit Hong Kong, where our CEO & Managing Director, Dr Anthony Filippis, presented Neurotech’s progress advancing NTI164. The Summit provided a great opportunity to meet with investors and discuss NTI164, our novel broad-spectrum oral cannabinoid therapy being developed for childhood neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome and PANDAS/PANS. We thank Ignite Partners, the organisers, and everyone who took the time to meet with us during the conference. $NTI

REMINDER | Our CEO & MD, Dr Anthony Filippis, is attending the Ignite Summit HK in Hong Kong, hosted at the Grand Hyatt, Wan Chai. Dr Filippis will be presenting on Day 1, Wednesday 15 April at 3:10pm, sharing an update on Neurotech’s clinical development programs and the advancement of NTI164 in paediatric neurological disorders. If you are attending the Summit, we welcome the opportunity to connect. #IgniteInvestmentSummit #HongKong #InvestorMeetings #LifeSciencesInvestment #Neurotech #ASX #NTI #IgniteSummitHK #Biotechnology #PaediatricNeurology

We’re presenting at the Ignite Investment Summit in Hong Kong this week, with our CEO & MD, Dr Anthony Filippis, representing Neurotech. Anthony will discuss NTI164, our broad-spectrum oral cannabinoid therapy, and its development as a novel therapy for childhood neurological and neurodevelopmental disorders. He will deliver a group presentation at 3:10pm HKT / 5:10pm AEST on Wednesday 15 April 2026, alongside a series of investor meetings across the Summit. If you are attending, we look forward to connecting. $NTI Presentation: api.investi.com.au/api/announceme…

Neurotech opens first site for phase III autism trial | $NTI Media coverage The Australian. theaustralian.com.au/business/stock… #Neurotech #NTI #Autism #ASD #Biotech

In case you missed it, our CEO & Managing Director, Dr Anthony Filippis, recently presented at the NWR Healthcare Conference, outlining clinical outcomes from NTI164 in Autism Spectrum Disorder. As Anthony noted, “We’ve shown that 84% of patients showed improvement within the first eight weeks of treatment with NTI164.” In the Phase II/III clinical trial, NTI164 demonstrated clinically meaningful improvements across core ASD symptom domains, including social responsiveness, anxiety, behaviour and communication. These outcomes continue to support NTI164's advancement into the pivotal Beyond Harmony Phase 3 clinical study, as we progress toward regulatory pathways in Australia and the United States. Watch the full $NTI replay here: youtube.com/watch?v=P8_AdN…

Our CEO & MD, Dr Anthony Filippis, will be attending the upcoming Ignite Summit HK in Hong Kong, hosted at the Grand Hyatt, Wan Chai. Dr Filippis will be presenting on Day 1, Wednesday 15 April at 3:10pm, sharing an update on Neurotech’s clinical development programs and the advancement of NTI164 in paediatric neurological disorders. If you are attending the Summit, we welcome the opportunity to connect. $NTI

On 2 April, we recognise World Autism Awareness Day. At Neurotech, we're advancing NTI164 through clinical development in Autism Spectrum Disorder, with a focus on addressing core symptoms and underlying neuroinflammatory pathways. The Beyond Harmony Phase 3 clinical study is now underway, designed to support regulatory submissions in Australia and the United States. We remain focused on developing new treatment options for children and families affected by ASD. Learn more about World Autism Understanding Month here: aspect.org.au/waum #WAUM2026 $NTI #WorldAutismAwarenessDay #AutismSpectrumDisorder #Neurotech #ASXNTI #ClinicalTrials #PaediatricNeurology #Autism

Autism data hits ‘registration benchmark’ as Neurotech prepares for Phase III clinical trial | Media coverage by @cannabiz_au. cannabiz.com.au/autism-data-hi… $NTI #Neurotech #Autism #ASD

The replay of our CEO & Managing Director, Dr Anthony Filippis’ presentation from today’s NWR Virtual Healthcare Conference is now available. Watch the full $NTI replay here: youtu.be/P8_AdN3_OWw?si… $NTI #Neurotech #Biotech #Webinar @NWRcomms

REMINDER | CEO & Managing Director Dr Anthony Filippis will present at the @NWRcomms Virtual Healthcare Conference tomorrow (25 March 2026), at 1:30pm AEDT. Investors, shareholders, and interested parties are invited to register for the session here: ➡️us02web.zoom.us/webinar/regist… A recording will be available after the live session via the same link, the Company’s website, and social media channels. Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au. For more information, visit: nwrcommunications.com/events/healthc… $NTI #Neurotech #HealthcareConference #Biotech #InvestorUpdate #Webinar #Fibrosis #MedicalResearch #ASX

Neurotech has been featured in a recent @theheraldsun article by Robyn Riley, highlighting our Phase 3 “Beyond Harmony” clinical study evaluating #NTI164 in paediatric patients with Autism Spectrum Disorder (#ASD). The article covers the progression of NTI164 through clinical development, following earlier studies demonstrating statistically significant and clinically meaningful improvements across multiple core ASD symptom domains and caregiver-reported quality-of-life measures. As our CEO Dr Anthony Filippis, said in the article, “Our earlier trials showed clinically meaningful and statistically significant improvements in the core symptoms of autism spectrum disorder.” Professor Michael Fahey also highlighted the importance of clinical studies, “I wouldn’t be doing it if I didn’t think there was potential and there are so few options as far as the autism space goes.” We thank the Herald Sun and journalist @rileyrobyn08 for the coverage. Read more: heraldsun.com.au/health/conditi… $NTI #AutismSpectrumDisorder #ClinicalTrials #Phase3 #PaediatricNeurology

Corporate Presentation: March 2026 View the full $NTI Presentation here: api.investi.com.au/api/announceme… #Neurotech #ASX #NTI #NTI164 #PaediatricNeurology

We’ve initiated the first clinical site for our Phase 3 “Beyond Harmony” trial evaluating NTI164 in paediatric patients with Autism Spectrum Disorder (ASD). The first site to be activated is Monash Children’s Hospital and is now open for patient screening and recruitment following receipt of all required regulatory approvals. The Phase 3 Beyond Harmony trial is a multi-centre, randomised, double-blind, placebo-controlled study designed to evaluate the efficacy, safety and tolerability of NTI164 in children diagnosed with ASD, targeting core symptoms and underlying neuroinflammatory mechanisms. Additional clinical sites are expected to be initiated in the coming months as the study progresses. Read the full ASX Announcement here: api.investi.com.au/api/announceme… $NTI #Neurotech #ASXNTI #AutismSpectrumDisorder #ASD #Phase3 #ClinicalTrial #NTI164 #PaediatricNeurology

We're pleased to share that CEO & Managing Director Dr Anthony Filippis will present at the @NWRcomms Virtual Healthcare Conference on Wednesday, 25 March 2026, at 1:30pm AEDT. Investors, shareholders, and interested parties are invited to register for the session here: ➡️us02web.zoom.us/webinar/regist… A recording will be available after the live session via the same link, the Company’s website, and social media channels. Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au. For more information, visit: nwrcommunications.com/events/healthc… $NTI #Neurotech #HealthcareConference #Biotech #InvestorUpdate #Webinar #ASX

In case you missed it: Neurotech was recently featured in @StockheadAU's Health & Biotech Investor Guide 2026, with host Tylah Tully highlighting our progress advancing NTI164 for paediatric neurological disorders. View the full $NTI guide here: stockhead.com.au/investor-guide… Watch the video below. 🔽

On 28 February we recognise Rare Disease Day, a global movement focused on improving access to diagnosis, care and therapies for the 300 million people worldwide living with a rare disease. At Neurotech, our focus is on supporting children and families affected by these conditions. This includes Rett syndrome, a rare and severe neurodevelopmental disorder with significant unmet medical need. NTI164 has received Orphan Drug Designation in the US and Europe and Rare Paediatric Disease Designation from the US FDA for Rett syndrome, reinforcing its development pathway in this indication. Beyond Rett syndrome, we are also advancing NTI164 in other serious paediatric neurological and neuroimmune disorders, including Autism Spectrum Disorder and PANS/PANDAS, where families continue to seek better treatment options. Rare Disease Day is a reminder that continued research, regulatory engagement and clinical development are critical to improving outcomes for children affected by complex neurological disorders. $NTI #RareDiseaseDay #RettSyndrome #RarePediatricDisease #OrphanDrug #Neurotech #ASX #NTI #PaediatricNeurology